RxDoctor Payments Data

Joseph Prigg

Physician Assistant · Lewes, DENPI 1245233105

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 135 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $766 and has fallen 92.0% since, to $62 in 2025. Among physician assistant clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,359in general payments, 2019–2025

Across 135 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$302
  • Novo Nordisk$238
  • GSK$223
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$206
  • AstraZeneca$177
  • Boehringer Ingelheim$165
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$2,359100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,359 in reported general payments places this provider in the 90th percentile of 527 physician assistant providers in Delaware.

See all physician assistant providers in Delaware

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide54$65,969
MounjaroTirzepatide24$47,659
TrulicityDulaglutide31$42,484
EliquisApixaban27$20,832
JanuviaSitagliptin Phosphate13$20,459
Tresiba Flextouch U-200Insulin Degludec16$18,883
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$16,888
JanumetSitagliptin Phos/Metformin Hcl18$16,226
OxycontinOxycodone Hcl33$16,067
FetzimaLevomilnacipran Hcl12$5,651
Atorvastatin Calcium376$5,492
Rosuvastatin Calcium145$3,676
Telmisartan47$3,184
Omeprazole160$3,161
Olmesartan Medoxomil121$3,130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$302$90,14255 claims
Novo NordiskOzempic$238$65,96954 claims
MerckJanuvia, Janumet$19$36,68431 claims
PfizerEliquis$95$20,83227 claims
GSKTrelegy Ellipta$223$16,88819 claims
AbbVieFetzima, Synthroid$157$7,94442 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 527 physician assistant providers in Delaware.

Other physician assistant in Lewes

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →